迈博药业-B（02181）于公告中披露，将在下一次股东周年大会上寻求授予董事一般性股份购回授权，规模最多为已发行股本的10%。截至本次公告披露日期，公司已发行股份总数为4,124,080,000股，故回购上限对应约412,408,000股。
根据公告，若有关授权获批，董事会将可在香港联合交易所有限公司进行购回，并由公司可合法动用的资金支付购回价款。董事会表示，此举旨在提升股东回报及优化资本结构，并强调相信该计划符合公司及股东的整体最佳利益。
公司股东周年大会将于2026年6月26日召开，届时若关于购回授权的决议案获正式通过，公司即可在授权有效期内酌情择机进行股份回购。董事会同时提醒，相关购回事项须遵守香港及开曼群岛法律要求，以及联交所上市规则的有关规定。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.